TOM FORD Announces Appointment of Haider Ackermann as Creative Director
4.9.2024 15:30:00 CEST | Business Wire | Press release
TOM FORD announces the appointment of Haider Ackermann as Creative Director, effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904332237/en/
Haider Ackermann appointed Creative Director, TOM FORD. (Photo Credit: Ethan James Green)
In his new role, Ackermann will assume the creative leadership across all TOM FORD fashion categories, including menswear, womenswear, accessories, and eyewear, and guide the creative vision for the overall brand. TOM FORD is owned by The Estée Lauder Companies Inc. (NYSE:EL) with the fashion business licensed to the Ermenegildo Zegna Group (NYSE:ZGN) and the eyewear business licensed to Marcolin SpA.
Founder Tom Ford said, “I have long been a great fan of Haider’s work. I find both his womenswear and menswear equally compelling. He is an incredible colorist, his tailoring is sharp, and above all he is modern. We share many of the same historical references, and I could not be more excited to see what he does with the brand. I suspect that I will be the first on my feet to applaud after his show in March.”
A French national born in Bogotá, Colombia, Ackermann's upbringing spanned Ethiopia, Chad, Algeria, The Netherlands, and Belgium, where he studied fashion at the Royal Academy of Fine Arts in Antwerp. Known for blending luxurious fabrics with impeccable tailoring, Ackermann has garnered acclaim for his avant-garde, yet wearable designs favored by celebrities.
“It is with tremendous pride that I will seek to honor the legacy of Tom Ford, a man I have long admired and have the utmost respect for,” said Ackermann. “I am much looking forward to what lies ahead.”
Ackermann's first collection will debut at Paris Fashion Week in March 2025. He will be based in Paris, reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies, and to Lelio Gavazza, CEO, TOM FORD FASHION, Ermenegildo Zegna Group.
“Haider stands out as one of the world's most visionary and inspiring talents in fashion. He draws on his deep affinity for global culture and the arts to create arresting fashion and memorable emotional connections. He is the ideal steward to usher TOM FORD into the future," said Jesel.
“I am extremely pleased to welcome Haider as Creative Director of TOM FORD. His unparalleled creativity, which is aligned with the brand's DNA, as well as his renowned experience in luxury will be instrumental in driving the fashion business forward during its next important phase of expansion. Working alongside the talented team at TOM FORD FASHION, Haider’s modern vision, for both men’s and women’s wear, will be essential as we advance and execute the many projects we have in development,” said Gavazza.
About TOM FORD
TOM FORD is a global design house offering exceptional luxury products across women’s and men’s fashion, accessories, eyewear and beauty. Founded in 2005 by Tom Ford, the brand has a presence in more than 100 markets globally and is widely recognized as the architect of luxury glamour. In 2023, The Estée Lauder Companies became the sole owner of the TOM FORD brand and all its intellectual property. In connection with the acquisition, The Estée Lauder Companies established long term licenses with Ermenegildo Zegna Group for TOM FORD FASHION and Marcolin for TOM FORD EYEWEAR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904332237/en/
Contacts
Press Contact:
Press Contact:
Giuseppe Torrisi
TOM FORD, Global Communications Director
Giuseppe.Torrisi@tomfordfashion.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom